These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23899641)

  • 41. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia.
    Kopala L; Honer WG
    Am J Psychiatry; 1994 Nov; 151(11):1714-5. PubMed ID: 7524373
    [No Abstract]   [Full Text] [Related]  

  • 42. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia.
    Iyo M; Shirayama Y; Watanabe H; Fujisaki M; Miyatake R; Fukami G; Shiina A; Nakazato M; Shiraishi T; Ookami T; Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1072-3. PubMed ID: 18262707
    [No Abstract]   [Full Text] [Related]  

  • 43. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study.
    Silver H; Barash I; Aharon N; Kaplan A; Poyurovsky M
    Int Clin Psychopharmacol; 2000 Sep; 15(5):257-61. PubMed ID: 10993127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding.
    Gentile S
    Arch Womens Ment Health; 2006 May; 9(3):158-9. PubMed ID: 16683078
    [No Abstract]   [Full Text] [Related]  

  • 45. The treatment of negative symptoms: pharmacological and methodological issues.
    Carpenter WT
    Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
    [No Abstract]   [Full Text] [Related]  

  • 46. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients.
    Ertugrul A; Anil Yagcioglu AE; Eni N; Yazici KM
    Psychiatry Clin Neurosci; 2005 Apr; 59(2):219-22. PubMed ID: 15823172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients.
    Di Lorenzo R; Tondelli G; Genedani S
    Int J Neuropsychopharmacol; 2001 Jun; 4(2):135-7. PubMed ID: 11466163
    [No Abstract]   [Full Text] [Related]  

  • 49. The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?
    Möller HJ
    Psychiatr Danub; 2016 Dec; 28(4):435-440. PubMed ID: 27855437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia.
    Purdon SE; Snaterse M
    Can J Psychiatry; 1998 Feb; 43(1):84-5. PubMed ID: 9494753
    [No Abstract]   [Full Text] [Related]  

  • 51. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clozapine augmentation with aripiprazole for negative symptoms.
    Clarke LA; Lindenmayer JP; Kaushik S
    J Clin Psychiatry; 2006 Apr; 67(4):675-6. PubMed ID: 16669737
    [No Abstract]   [Full Text] [Related]  

  • 53. Fluvoxamine-clozapine interaction: time-dependent?
    Lu ML; Lane HY; Chang WH
    J Clin Psychopharmacol; 2002 Aug; 22(4):439-40. PubMed ID: 12172350
    [No Abstract]   [Full Text] [Related]  

  • 54. Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients.
    Silver H; Mandiuk N; Einoch R; Susser E; Danovich L; Bilker W; Youdim M; Weinreb O
    Int Clin Psychopharmacol; 2015 May; 30(3):158-66. PubMed ID: 25756551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The treatment of OCD].
    Sumitani S; Ohmori T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):442-5. PubMed ID: 12877022
    [No Abstract]   [Full Text] [Related]  

  • 56. [Depressive symptoms in schizophrenia].
    Gerard A
    Encephale; 1998 Jul; 24 Spec No 1():24-6. PubMed ID: 9809250
    [No Abstract]   [Full Text] [Related]  

  • 57. Fluvoxamine improved cognitive impairments in a patient with schizophrenia.
    Niitsu T; Shirayama Y; Fujisaki M; Hashimoto K; Iyo M
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1345-6. PubMed ID: 20600473
    [No Abstract]   [Full Text] [Related]  

  • 58. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial.
    Mico' U; Bruno A; Pandolfo G; Maria Romeo V; Mallamace D; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
    Int Clin Psychopharmacol; 2011 Nov; 26(6):303-10. PubMed ID: 21934625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
    Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
    J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.